Association of Ivermectin use on mortality in patients with COVID-19

Authors

Keywords:

ivermectin, therapeutic, coronavirus infections, COVID-19, SARS-CoV-2.

Abstract

Introduction: Ivermectin has been used to prevent and treat COVID-19 patients, however, recent research has shown that its efficacy does not justify its use.
Objective: To determine the association between the use of Ivermectin, mortality and 3 other indicators in patients with COVID-19.
Methods: Observational retrospective cohort study. We reviewed the medical records of patients who were hospitalized between April and October 2020, who in addition to standard treatment (oxygen therapy, corticosteroid and enoxaparin), received treatment with Ivermectin for severe or critical COVID-19 pneumonia. Four outcome variables were measured: mortality, indication for transfer to the Intensive Care Unit days of hospitalization and time required for high-flow oxygen therapy.
Results: Of patients, 42 % (126) died and 52 % (159) had indication for transfer to the Intensive Care Unit. In the multivariate analysis those who took a higher dose had a greater indication for transfer to Intensive Care Unit (RRa: 1.10; IC 95 %: 1.01-1.20; p-value= 0.035), days of hospitalization (coefficient: 5,07; IC 95 %: 2.15-11.92; p-value< 0.001) and time requiring high-flow oxygen therapy (coefficient: 3.33; IC 95 %: 1.56-7.09; p-value= 0.002).
Conclusion: Patients who received Ivermectin were more likely to be referred to the Intensive Care Unit, had a longer hospital stay, and required more time on high-flow oxygen, without finding a relationship with mortality in patients hospitalized for SARS-CoV-2. The administration of Ivermectin before or during hospitalization had no benefit.

Downloads

Download data is not yet available.

Author Biographies

Andrea Lucia Mujica Alvarez, Hospital San José

Médica internista. Hospital San José

Christian Richard Mejia, Universidad Continental. Huancayo, Perú.

Docente

References

1. Hamed MA. An overview on COVID-19: reality and expectation. Bulletin of the National Research Centre. 2020 [acceso: 05/01/2021]; 44(1):86-96. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266424/

2. Dixit A, Yadav R, Singh AV. Ivermectin: Potential role as repurposed drug for COVID-19. Malays J Med Sci. 2020 [acceso: 07/01/2021]; 27(4):154-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444833/

3. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. 2020 [acceso: 04/01/2021]; 73(9):593-602. Disponible en: https://www.nature.com/articles/s41429-020-0336-z

4. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, et al. Infectious diseases society of america guidelines on the treatment and management of patients with Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2020 [acceso: 05/01/2021]; 1(1):1-61. Disponible en: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa478/5825667?login=false

5. Paumgartten FJR, Oliveira ACAX de. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Ciênc saúde coletiva. 2020 [acceso: 07/01/2021]; 25(9): 3413-9. Disponible en: https://www.scielo.br/j/csc/a/GQwLcBQZmGYp7mK3V6r7tFt/?lang=en

6. Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. 2020 [acceso: 04/01/2021]; 1(1):1-4. Disponible en: https://link.springer.com/article/10.1007/s00210-020-01902-5

7. Elkholy KO, Hegazy O, Erdinc B, Abowali H. Ivermectin: A closer look at a potential remedy. Cureus. 2020; 12(9): 10378-85. DOI: 10.7759/cureus.10378

8. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal. 2012 [acceso: 04/01/2021]; 443(3):851-6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327999/

9. Ministerio de Salud del Perú. Documento Técnico: Prevención, Diagnóstico y Tratamiento de personas afectadas por COVID-19 en el Perú. Resolución Ministerial N° 193-2020-MINSA. Lima: MINSA; 2020 [acceso:15/01/2021]. Disponible en: https://www.gob.pe/institucion/minsa/informes-publicaciones/473587-prevencion-diagnostico-ytratamiento-de-personas-afectadas-por-covid-19-en-el-peru

10. Saha Podder C, Chowdhury N, Ibne Sina M, Wasin Mohosin H. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC Journal of Medical Science. 2020 [acceso: 09/01/2021]; 4(2):1-10. Disponible en: https://www.banglajol.info/index.php/IMCJMS/article/view/52826

11. Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world effectiveness of Hydroxychloroquine, Azithromycin, and Ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide healthcare system in Peru. MedRxiv [preprint]. 2020 [acceso: 05/01/2021]: [aprox. 25 p]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v3.full.pdf

12. Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLOS ONE. 2020 [acceso: 09/01/2021]; 15(11):1-6. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242184

13. Spoorthi V, Sasank S. Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2. IAIM. 2020 [acceso: 08/01/2021]; 7(10):177-82. Disponible en: https://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf

14. OMS. La OMS interrumpe los grupos de tratamiento de la COVID-19 con hidroxicloroquina y con la combinación lopinavir/ritonavir. WHO, Noticias; 2020. [acceso: 07/01/2021]. Disponible en: https://www.who.int/es/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19

15. Mohiuddin Chowdhury ATM, Shahbaz M, Karim M, Islam J, Dan G, He S. A comparative study on Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients. EJMO; 2021; 5(1): 63-50. DOI: 10.14744/ejmo.2021.16263

16. Morgenstern J, Redondo JN, De León A, Canela JM, Torres N, Tavares J, et al. The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. MedRxiv [preprint]. 2020 [acceso: 08/01/2021]:1-16. DOI: 10.1101/2020.10.29.20222505

17. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020 [acceso: 09/01/2021]; 38(Supplement):10-5. Disponible en: https://www.banglajol.info/index.php/JBCPS/article/view/47512

18. PAHO/WHO. Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Pan American Health Organization; 2020. [acceso: 15/01/2021]. Disponible en: https://www.paho.org/en/documents/ongoing-living-update-potential-covid-19-therapeutics-summary-rapid-systematic-reviews

19. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J. ICON (Ivermectin in COVID Nineteen) study: Use of Ivermectin is associated with lower mortality in hospitalized patients with COVID19. MedRxiv [preprint]. 2020 [acceso: 04/01/2021]:1-18. DOI: 10.1101/2020.06.06.20124461

20. Niaee M, Gheibi N, Namdar P, Allami A, Zolghadr L, Javadi A, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Researsh Square [preprint]. 2020 [acceso: 12/01/2021]:1-18 Disponible en: https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=6;spage=266;epage=273;aulast=Shakhsi

21. Elgazzar A, Eltaweel A, Youssef S, Hany B, Hafez M, Moussa H. Efficacy and safety of Ivermectin for treatment and prophylaxis of COVID-19 pandemic. Researsh Square [preprint]. 2020: 1-10. DOI: 10.21203/rs.3.rs-100956/v4

22. Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Kornfeld H, et al. Review of the emerging evidence demonstrating the efficacy of Ivermectin in the prophylaxis and treatment of COVID-19. Frontiers in Public Health. 2020 [acceso: 10/01/2021]; 1(1):1-31. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/

Downloads

Published

2022-04-30

How to Cite

1.
Mujica Alvarez AL, Mejia CR. Association of Ivermectin use on mortality in patients with COVID-19. Rev Cubana Med Milit [Internet]. 2022 Apr. 30 [cited 2025 Apr. 19];51(2):e02201913. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/1913

Issue

Vol. 51 No. 2 (2022): April - June

Section

Research Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.